

Mark B Pepys

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8432822/publications.pdf>

Version: 2024-02-01

136
papers

30,890
citations

15495

65
h-index

11601

135
g-index

137
all docs

137
docs citations

137
times ranked

28072
citing authors

#	ARTICLE	IF	CITATIONS
1	C-reactive protein: a critical update. <i>Journal of Clinical Investigation</i> , 2003, 111, 1805-1812.	3.9	2,941
2	C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2004, 350, 1387-1397.	13.9	2,608
3	The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina. <i>New England Journal of Medicine</i> , 1994, 331, 417-424.	13.9	2,159
4	C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. <i>Lancet, The</i> , 2010, 375, 132-140.	6.3	1,946
5	C-reactive protein: a critical update. <i>Journal of Clinical Investigation</i> , 2003, 111, 1805-1812.	3.9	1,673
6	C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men. <i>Circulation</i> , 1999, 99, 237-242.	1.6	1,672
7	Common core structure of amyloid fibrils by synchrotron X-ray diffraction 1 Edited by F. E. Cohen. <i>Journal of Molecular Biology</i> , 1997, 273, 729-739.	2.0	1,590
8	Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. <i>Nature</i> , 1997, 385, 787-793.	13.7	1,061
9	C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. <i>New England Journal of Medicine</i> , 2012, 367, 1310-1320.	13.9	909
10	The physiological structure of human C-reactive protein and its complex with phosphocholine. <i>Structure</i> , 1999, 7, 169-177.	1.6	656
11	Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis. <i>New England Journal of Medicine</i> , 2002, 346, 1786-1791.	13.9	621
12	Targeting C-reactive protein for the treatment of cardiovascular disease. <i>Nature</i> , 2006, 440, 1217-1221.	13.7	621
13	Amyloidosis. <i>Annual Review of Medicine</i> , 2006, 57, 223-241.	5.0	557
14	Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. <i>BMJ: British Medical Journal</i> , 2011, 342, d548-d548.	2.4	530
15	Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. <i>Lancet, The</i> , 2001, 358, 24-29.	6.3	520
16	Evaluation of Systemic Amyloidosis by Scintigraphy with ¹²³ I-Labeled Serum Amyloid P Component. <i>New England Journal of Medicine</i> , 1990, 323, 508-513.	13.9	497
17	Effect of alcohol consumption on systemic markers of inflammation. <i>Lancet, The</i> , 2001, 357, 763-767.	6.3	496
18	Structure of pentameric human serum amyloid P component. <i>Nature</i> , 1994, 367, 338-345.	13.7	471

#	ARTICLE	IF	CITATIONS
19	C-Reactive Protein, Insulin Resistance, Central Obesity, and Coronary Heart Disease Risk in Indian Asians From the United Kingdom Compared With European Whites. <i>Circulation</i> , 2001, 104, 145-150.	1.6	382
20	Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. <i>British Journal of Haematology</i> , 2003, 122, 78-84.	1.2	370
21	Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP ϵ met ³⁰). <i>Clinical Genetics</i> , 1991, 40, 242-246.	1.0	350
22	The protofilament substructure of amyloid fibrils ¹¹ Edited by F. E. Cohen. <i>Journal of Molecular Biology</i> , 2000, 300, 1033-1039.	2.0	332
23	Three dimensional structure of human C-reactive protein. <i>Nature Structural and Molecular Biology</i> , 1996, 3, 346-354.	3.6	308
24	Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. <i>New England Journal of Medicine</i> , 2015, 373, 1106-1114.	13.9	304
25	Enhanced Inflammatory Response to Coronary Angioplasty in Patients With Severe Unstable Angina. <i>Circulation</i> , 1998, 98, 2370-2376.	1.6	292
26	Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. <i>Nature</i> , 2010, 468, 93-97.	13.7	290
27	Human plasma fibrinogen is synthesized in the liver. <i>Blood</i> , 2007, 109, 1971-1974.	0.6	251
28	Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. <i>Nature Medicine</i> , 1997, 3, 855-859.	15.2	239
29	Immunoradiometric Assay of Circulating C-Reactive Protein: Age-related Values in the Adult General Population. <i>Clinical Chemistry</i> , 2000, 46, 934-938.	1.5	218
30	Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. <i>Nature Medicine</i> , 2001, 7, 485-487.	15.2	206
31	Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8309-8314.	3.3	194
32	Interleukin 6 Influences Germinal Center Development and Antibody Production via a Contribution of C3 Complement Component. <i>Journal of Experimental Medicine</i> , 1998, 188, 1895-1906.	4.2	177
33	Inflammation and Endothelial Function. <i>Circulation</i> , 2005, 111, 1530-1536.	1.6	175
34	Hereditary Systemic Amyloidosis Due to Asp76Asn Variant β_2 -Microglobulin. <i>New England Journal of Medicine</i> , 2012, 366, 2276-2283.	13.9	172
35	Obesity Is an Important Determinant of Baseline Serum C-Reactive Protein Concentration in Monozygotic Twins, Independent of Genetic Influences. <i>Circulation</i> , 2004, 109, 3022-3028.	1.6	168
36	AMYLOIDOSIS: A REVIEW OF RECENT DIAGNOSTIC AND THERAPEUTIC DEVELOPMENTS. <i>British Journal of Haematology</i> , 1997, 99, 245-256.	1.2	166

#	ARTICLE	IF	CITATIONS
37	Acute phase response and evolution of familial Mediter ranean fever. Lancet, The, 1999, 353, 1415.	6.3	160
38	Enhanced inflammatory response in patients with preinfarction unstable angina. Journal of the American College of Cardiology, 1999, 34, 1696-1703.	1.2	144
39	Genetic Effects on Baseline Values of C-Reactive Protein and Serum Amyloid A Protein: A Comparison of Monozygotic and Dizygotic Twins. Clinical Chemistry, 2004, 50, 130-134.	1.5	139
40	Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 1214-1218.	2.4	137
41	Plasma Protein Acute-Phase Response in Unstable Angina Is Not Induced by Ischemic Injury. Circulation, 1996, 94, 2373-2380.	1.6	134
42	Rapid Automated High Sensitivity Enzyme Immunoassay of C-Reactive Protein. Clinical Chemistry, 1998, 44, 1358-1361.	1.5	123
43	Multinucleated Giant Cells Are Specialized for Complement-Mediated Phagocytosis and Large Target Destruction. Cell Reports, 2015, 13, 1937-1948.	2.9	123
44	Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself. Circulation Research, 2005, 97, e97-103.	2.0	121
45	Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses 1 Edited by R. Huber. Journal of Molecular Biology, 1997, 272, 408-422.	2.0	113
46	Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 2006, 107, 1227-1229.	0.6	113
47	Refinement of the Association of Serum C-reactive Protein Concentration and Coronary Heart Disease Risk by Correction for Within-Subject Variation over Time: The MONICA Augsburg Studies, 1984 and 1987. American Journal of Epidemiology, 2003, 158, 357-364.	1.6	111
48	Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy. Journal of Molecular Biology, 2001, 311, 241-247.	2.0	110
49	A novel mechanoenzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Molecular Medicine, 2015, 7, 1337-1349.	3.3	109
50	Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. British Journal of Haematology, 2010, 148, 760-767.	1.2	106
51	SAA ₁ alleles as risk factors in reactive systemic AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 262-265.	1.4	104
52	CRP or not CRP? That Is the Question. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1091-1094.	1.1	98
53	Comparative analyses of pentraxins: implications for protomer assembly and ligand binding. Structure, 1994, 2, 1017-1027.	1.6	96
54	Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE ^{0/0} mice. Atherosclerosis, 2008, 196, 248-255.	0.4	96

#	ARTICLE	IF	CITATIONS
55	Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	94
56	Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1539-1544.	3.3	91
57	Infection With <i>Helicobacter pylori</i> Is Not a Major Independent Risk Factor for Stable Coronary Heart Disease. <i>Circulation</i> , 1999, 100, 2326-2331.	1.6	83
58	Complement Factor H Binds to Denatured Rather than to Native Pentameric C-reactive Protein. <i>Journal of Biological Chemistry</i> , 2008, 283, 30451-30460.	1.6	82
59	Structure, Folding Dynamics, and Amyloidogenesis of D76N β 2-Microglobulin. <i>Journal of Biological Chemistry</i> , 2013, 288, 30917-30930.	1.6	80
60	Serum amyloid P component in chronic renal failure and dialysis. <i>Clinica Chimica Acta</i> , 1991, 200, 191-199.	0.5	79
61	Pathogenetic mechanisms of amyloid A amyloidosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 16115-16120.	3.3	79
62	C-reactive protein and cardiovascular disease: Weighing the evidence. <i>Current Atherosclerosis Reports</i> , 2006, 8, 421-428.	2.0	75
63	Hereditary renal amyloidosis associated with variant lysozyme in a large English family. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 2639-2644.	0.4	72
64	Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. <i>Kidney International</i> , 1998, 53, 276-281.	2.6	70
65	Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 709-713.	3.3	68
66	Plasminogen activation triggers transthyretin amyloidogenesis in vitro. <i>Journal of Biological Chemistry</i> , 2018, 293, 14192-14199.	1.6	68
67	Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?. <i>Immunology</i> , 2004, 112, 255-264.	2.0	63
68	Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7619-7623.	3.3	63
69	Infusion of Pharmaceutical-Grade Natural Human C-Reactive Protein Is Not Proinflammatory in Healthy Adult Human Volunteers. <i>Circulation Research</i> , 2014, 114, 672-676.	2.0	63
70	Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. <i>Age and Ageing</i> , 1997, 26, 153-158.	0.7	57
71	Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. <i>Kidney International</i> , 1996, 50, 282-289.	2.6	56
72	Trapping of palindromic ligands within native transthyretin prevents amyloid formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20483-20488.	3.3	55

#	ARTICLE	IF	CITATIONS
73	DOMINO HEPATIC TRANSPLANTATION USING THE LIVER FROM A PATIENT WITH FAMILIAL AMYLOID POLYNEUROPATHY. <i>Transplantation</i> , 1998, 65, 1496-1498.	0.5	55
74	C-reactive protein is essential for innate resistance to pneumococcal infection. <i>Immunology</i> , 2014, 142, 414-420.	2.0	51
75	Molecular chaperone properties of serum amyloid P component. <i>FEBS Letters</i> , 2000, 473, 199-202.	1.3	49
76	C-Reactive Protein and Coronary Disease. <i>Circulation</i> , 2009, 120, 2036-2039.	1.6	49
77	The Pentraxins 1975–2018: Serendipity, Diagnostics and Drugs. <i>Frontiers in Immunology</i> , 2018, 9, 2382.	2.2	49
78	Human Serum Amyloid P Component Protects against <i>Escherichia coli</i> O157:H7 Shiga Toxin 2 In Vivo: Therapeutic Implications for Hemolytic-Uremic Syndrome. <i>Journal of Infectious Diseases</i> , 2006, 193, 1120-1124.	1.9	48
79	Production of Granulocyte Colony-Stimulating Factor in the Nonspecific Acute Phase Response Enhances Host Resistance to Bacterial Infection. <i>Journal of Immunology</i> , 2002, 169, 913-919.	0.4	47
80	Immunohistochemical Studies of Amyloid P Component Distribution in Normal Human Skin. <i>Journal of Investigative Dermatology</i> , 1983, 80, 86-90.	0.3	43
81	Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP. <i>Journal of Molecular Biology</i> , 1997, 269, 570-578.	2.0	43
82	Molecular characterization of <i>Limulus polyphemus</i> C-reactive protein. I. Subunit composition. <i>FEBS Journal</i> , 1993, 214, 91-97.	0.2	42
83	Amyloid and the Gut. <i>Digestive Diseases</i> , 1997, 15, 155-171.	0.8	36
84	Serum C-reactive protein levels in the management of infection in acute leukaemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1984, 20, 319-325.	0.9	35
85	Amyloid P Component Binds to Keratin Bodies in Human Skin and to Isolated Keratin Filament Aggregates In Vitro. <i>Journal of Investigative Dermatology</i> , 1988, 91, 22-28.	0.3	35
86	Structural basis of ligand specificity in the human pentraxins, C-reactive protein and serum amyloid P component. <i>Journal of Molecular Recognition</i> , 2011, 24, 371-377.	1.1	34
87	Human C-Reactive Protein Does Not Protect against Acute Lipopolysaccharide Challenge in Mice. <i>Journal of Immunology</i> , 2003, 171, 6046-6051.	0.4	33
88	Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay. <i>Journal of Immunological Methods</i> , 2013, 390, 63-73.	0.6	33
89	Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. <i>Journal of Immunological Methods</i> , 2012, 384, 92-102.	0.6	32
90	Determination of C-Reactive Protein: Comparison of Three High-Sensitivity Immunoassays. <i>Clinical Chemistry</i> , 2003, 49, 1691-1695.	1.5	30

#	ARTICLE	IF	CITATIONS
91	C-reactive protein is neither a marker nor a mediator of atherosclerosis. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 234-235.	2.0	29
92	Markers of inflammation in women on different hormone replacement therapies. <i>Annals of Medicine</i> , 2003, 35, 353-361.	1.5	27
93	Science and serendipity. <i>Clinical Medicine</i> , 2007, 7, 562-578.	0.8	27
94	Imaging of experimental amyloidosis with ¹³¹ I-labeled serum amyloid p component. <i>Arthritis and Rheumatism</i> , 1987, 30, 1303-1306.	6.7	26
95	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8274-8283.	2.9	25
96	MHC typing in variant Creutzfeldt-Jakob disease. <i>Lancet, The</i> , 2003, 361, 487-489.	6.3	24
97	C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target?. <i>European Heart Journal</i> , 2021, 42, 2280-2283.	1.0	24
98	Tissue Vitronectin in Normal Adult Human Dermis Is Non-Covalently Bound to Elastic Tissue. <i>Journal of Investigative Dermatology</i> , 1991, 96, 747-753.	0.3	22
99	Protection of Human Podocytes from Shiga Toxin 2-Induced Phosphorylation of Mitogen-Activated Protein Kinases and Apoptosis by Human Serum Amyloid P Component. <i>Infection and Immunity</i> , 2014, 82, 1872-1879.	1.0	22
100	Tissue Amyloid P Component in Normal Human Dermis is Non-covalently Associated with Elastic Fiber Microfibrils. <i>Journal of Investigative Dermatology</i> , 1989, 92, 53-58.	0.3	21
101	Scintigraphy with ¹²³ I-Serum Amyloid P Component in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 1998, 12, 208-210.	0.6	21
102	C-Reactive Protein Risk Prediction: Low Specificity, High Sensitivity. <i>Annals of Internal Medicine</i> , 2002, 136, 550.	2.0	21
103	Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular A β amyloid deposits <i>in vivo</i> . <i>Open Biology</i> , 2016, 6, 150202.	1.5	21
104	Tolerance and immunity to the inducible self antigen C-reactive protein in transgenic mice. <i>European Journal of Immunology</i> , 1995, 25, 3489-3495.	1.6	18
105	Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 245-249.	6.7	17
106	A molecular correlate of clinicopathology in transthyretin amyloidosis. <i>Journal of Pathology</i> , 2009, 217, 1-3.	2.1	16
107	Correlation of disease activity in systemic vasculitis with serum C-reactive protein measurement. A prospective study of thirty-eight patients. <i>European Journal of Clinical Investigation</i> , 1985, 15, 89-94.	1.7	15
108	Normal circulating serum amyloid P component concentration in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 56, 2013-2017.	6.7	14

#	ARTICLE	IF	CITATIONS
109	Is leptin an important physiological regulator of CRP?. <i>Nature Medicine</i> , 2007, 13, 17-18.	15.2	14
110	Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies. <i>Journal of Proteomics</i> , 2017, 165, 113-118.	1.2	14
111	Molecular characterization of <i>Limulus Polyphemus</i> C-reactive protein. II. Asparagine-linked oligosaccharides. <i>FEBS Journal</i> , 1993, 214, 99-110.	0.2	13
112	Î²-Edge Interactions in a Pentadecameric Human Antibody V _H Domain. <i>Journal of Molecular Biology</i> , 2007, 367, 603-608.	2.0	13
113	Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1. <i>PLoS ONE</i> , 2018, 13, e0197299.	1.1	13
114	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. <i>Nature Communications</i> , 2021, 12, 7112.	5.8	13
115	Murine type II collagen arthritis: Association of an acute-phase response with clinical course. <i>Arthritis and Rheumatism</i> , 1986, 29, 1131-1138.	6.7	12
116	Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils. <i>Journal of Biological Chemistry</i> , 2020, 295, 11379-11387.	1.6	12
117	Interaction of serum amyloid P component with hexanoyl bis(DL-proline) (CPHPC). <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2014, 70, 2232-2240.	2.5	11
118	Echocardiographic assessment of cardiac involvement in systemic AL amyloidosis in relation to whole body amyloid load measured by serum amyloid P component (SAP) clearance. <i>American Journal of Cardiology</i> , 1997, 80, 1104-1108.	0.7	10
119	Lack of seasonal variation in C-reactive protein. <i>Clinical Chemistry</i> , 2002, 48, 575-7.	1.5	10
120	Influenza virus infection is not affected by serum amyloid P component. <i>Molecular Medicine</i> , 2002, 8, 9-15.	1.9	9
121	The MHC class II-restricted T cell response of C57BL/6 mice to human C-reactive protein: Homology to self and the selection of T cell epitopes and T cell receptors. <i>Molecular Immunology</i> , 1997, 34, 115-124.	1.0	8
122	Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1995, 2, 163-166.	1.4	7
123	Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013, 20, 93-98.	1.4	7
124	Immunoradiometric assay for human serum amyloid P component. <i>Journal of Immunological Methods</i> , 2011, 371, 18-24.	0.6	6
125	Dementia in the older population is associated with neocortex content of serum amyloid P component. <i>Brain Communications</i> , 2021, 3, fcab225.	1.5	5
126	Targeted treatment for amyloidosis. <i>Israel Medical Association Journal</i> , 2014, 16, 277-80.	0.1	5

#	ARTICLE	IF	CITATIONS
127	Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP). <i>Blood</i> , 2015, 126, 1836-1836.	0.6	4
128	Dame Sheila Patricia Violet Sherlock. 31 March 1918 – 30 December 2001 Elected FRS 2001. <i>Biographical Memoirs of Fellows of the Royal Society</i> , 2003, 49, 475-493.	0.1	2
129	Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice. <i>Immunology</i> , 2004, 112, 250-254.	2.0	2
130	Attention to Detail in the Selection of Words in Epidemiologic Research Reports. <i>American Journal of Epidemiology</i> , 2014, 179, 795-796.	1.6	2
131	Bifunctional crosslinking ligands for transthyretin. <i>Open Biology</i> , 2015, 5, 150105.	1.5	2
132	Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 5-6.	1.4	2
133	C-reactive protein and cardiovascular disease: Weighing the evidence. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 72-79.	0.8	1
134	Jack Pepys (May 15, 1914–September 9, 1996): A personal recollection. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 718-720.	1.5	1
135	LIVER TRANSPLANTATION FOR END STAGE HEPATIC AMYLOIDOSIS.. <i>Transplantation</i> , 2000, 69, S139.	0.5	0
136	Transthyretin amyloidosis: new answers but many questions. <i>Journal of Internal Medicine</i> , 2021, 289, 933-935.	2.7	0